Repeated TLR9 Stimulation Results in Macrophage Activation Syndrome-like Disease in Mice
Overview
Authors
Affiliations
Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are 2 similar diseases characterized by a cytokine storm, overwhelming inflammation, multiorgan dysfunction, and death. Animal models of HLH suggest that disease is driven by IFN-γ produced by CD8⁺ lymphocytes stimulated by persistent antigen exposure. In these models and patients with "primary" HLH, the antigen persists due to genetic defects, resulting in ineffective cytotoxic responses by CD8⁺ T cells and poor pathogen clearance. However, infectious triggers are often not identified in patients with MAS, and some patients with HLH or MAS lack defects in cytotoxic T cell killing. Herein, we show that repeated stimulation of TLR9 produced an HLH/MAS-like syndrome on a normal genetic background, without exogenous antigen. Like previous HLH models, TLR9-induced MAS was IFN-γ dependent; however, unlike other models, disease did not require lymphocytes. We further showed that IL-10 played a protective role in this model and that blocking IL-10 signaling led to the development of hemophagocytosis. IL-10 may therefore be an important target for the development of effective therapeutics for MAS. Our data provide insight into MAS-like syndromes in patients with inflammatory diseases in which there is chronic innate immune activation but no genetic defects in cytotoxic cell function.
Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review.
Vassilopoulos A, McCormick W, Lakhani A Brown J Hosp Med. 2025; 1(3):37667.
PMID: 40046595 PMC: 11878877. DOI: 10.56305/001c.37667.
Development of anti-murine IL-18 binding protein antibodies to stimulate IL-18 bioactivity.
Huard A, Fauteux-Daniel S, Goldstein J, Martin P, Jarlborg M, Andries J J Immunol. 2025; 214(1):180-191.
PMID: 40018678 PMC: 7617445. DOI: 10.1093/jimmun/vkae022.
Weal and woe of interleukin-18 in the T cell therapy of cancer.
Kessel C, Rossig C, Abken H J Immunother Cancer. 2025; 13(1.
PMID: 39809514 PMC: 11749219. DOI: 10.1136/jitc-2024-010545.
Avrusin I, Bregel L, Efremova O, Kostik M Biomedicines. 2025; 12(12.
PMID: 39767774 PMC: 11673122. DOI: 10.3390/biomedicines12122868.
Yu L, Li Y, Li W, Zhang Y, He W, Tang X Front Immunol. 2024; 15:1474429.
PMID: 39676859 PMC: 11638164. DOI: 10.3389/fimmu.2024.1474429.